First patients test groundbreaking oral cancer pill
NCT ID NCT05159700
Summary
This is the first-ever study in humans of a new oral medication called PRJ1-3024 for people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see how the body handles the drug. Researchers will also look for early signs that the drug might help shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Christ Hospital
Cincinnati, Ohio, 21073, United States
-
Mays Cancer Center
San Antonio, Texas, 78229, United States
-
NEXT Oncology
Austin, Texas, 73301, United States
-
NEXT Oncology
Fairfax, Virginia, 22031, United States
-
Sarah Cannon Research Institute at Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
Sarah Cannon Research Institute at HealthONE
Denver, Colorado, 80218, United States
Conditions
Explore the condition pages connected to this study.